INTEGRIN-MEDIATED DRUG TARGETING

摘要

The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to alpha_vbeta₃ integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and alpha_vbeta₃ integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.